To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00991419

Enrollment

Registered

2009-10-08

Start date

2010-02-28

Completion date

2011-08-31

Last updated

2013-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

PET, Alzheimer's disease, diagnostic

Brief summary

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.

Interventions

DRUG[18F]AZD4694

\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or female, of any race or/ethnicity * ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician

Exclusion criteria

* Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse * Participated in a PET study within the last 12 months * Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
PET Measurements	Day 1 and Day 7

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026